OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
000423$52.2659

Dong-E-E-Jiao Co Ltd

PharmaceuticalsVerified

Dong-E-E-Jiao maintains a strong liquidity position, with a current ratio of 3.69 and a low debt-to-equity ratio of 0.01, indicating minimal leverage and strong balance sheet health. The company's market price of 52.26 CNY yields a price-to-earnings ratio of 19.36 and a price-to-book ratio of 3.26, suggesting a moderate valuation relative to its book value and earnings. Free cash flow of 163,067,300 CNY and operating cash flow of 2,289,207,780 CNY further support its ability to fund operations and reinvest in the business. Profitability metrics show a return on equity of 16.82% and a return on assets of 12.99%, both of which are strong indicators of efficient capital use and asset management. The company's gross profit of 4,921,267,020 CNY and operating income of 2,070,532,280 CNY reflect a healthy margin structure, although the net income of 1,738,741,090 CNY is slightly lower, indicating some operating expenses or tax pressures. Geographically, the company is heavily concentrated in the Chinese market, with no disclosed international revenue segments. This concentration may expose the company to domestic regulatory and economic risks, although it also allows for deep market penetration and brand recognition. The company's revenue of 6,700,474,180 CNY and net income of 1,738,741,090 CNY suggest a stable growth trajectory, supported by strong cash flow generation and a solid balance sheet. Analysts have set a mean price target of 74.69 CNY, with a median of 75.00 CNY, indicating a positive outlook for the stock. Risk factors include a medium liquidity risk due to negative net cash after subtracting total debt, and a low dilution risk, with no significant dilution potential in the near term. The company's capital structure is conservative, with long-term debt of only 62,260,140 CNY, and a capital expenditure of -82,671,900 CNY, indicating a focus on cash preservation rather than aggressive expansion. Recent events include strong analyst sentiment, with a mean recommendation of 1.78 (1=strong buy, 5=strong sell), and a total of 9 buy recommendations out of 9 total analyst ratings. This indicates a generally positive outlook from the investment community.

30-day price · 000423-5.67 (-10.2%)
Low$49.53High$56.45Close$49.65As of22 May, 00:00 UTC
Profile
CompanyDong-E-E-Jiao Co Ltd
Ticker000423.SZ
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Dong-E-E-Jiao Co Ltd is a Chinese pharmaceutical company that produces and sells traditional Chinese medicine (TCM) products, including the well-known Dong'e Ejiao, a gelatin-based product derived from donkey hide.

Classification. The company is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a high confidence level of 0.92.

Dong-E-E-Jiao maintains a strong liquidity position, with a current ratio of 3.69 and a low debt-to-equity ratio of 0.01, indicating minimal leverage and strong balance sheet health. The company's market price of 52.26 CNY yields a price-to-earnings ratio of 19.36 and a price-to-book ratio of 3.26, suggesting a moderate valuation relative to its book value and earnings. Free cash flow of 163,067,300 CNY and operating cash flow of 2,289,207,780 CNY further support its ability to fund operations and reinvest in the business. Profitability metrics show a return on equity of 16.82% and a return on assets of 12.99%, both of which are strong indicators of efficient capital use and asset management. The company's gross profit of 4,921,267,020 CNY and operating income of 2,070,532,280 CNY reflect a healthy margin structure, although the net income of 1,738,741,090 CNY is slightly lower, indicating some operating expenses or tax pressures. Geographically, the company is heavily concentrated in the Chinese market, with no disclosed international revenue segments. This concentration may expose the company to domestic regulatory and economic risks, although it also allows for deep market penetration and brand recognition. The company's revenue of 6,700,474,180 CNY and net income of 1,738,741,090 CNY suggest a stable growth trajectory, supported by strong cash flow generation and a solid balance sheet. Analysts have set a mean price target of 74.69 CNY, with a median of 75.00 CNY, indicating a positive outlook for the stock. Risk factors include a medium liquidity risk due to negative net cash after subtracting total debt, and a low dilution risk, with no significant dilution potential in the near term. The company's capital structure is conservative, with long-term debt of only 62,260,140 CNY, and a capital expenditure of -82,671,900 CNY, indicating a focus on cash preservation rather than aggressive expansion. Recent events include strong analyst sentiment, with a mean recommendation of 1.78 (1=strong buy, 5=strong sell), and a total of 9 buy recommendations out of 9 total analyst ratings. This indicates a generally positive outlook from the investment community.
Key takeaways
  • Dong-E-E-Jiao has a strong liquidity position with a current ratio of 3.69 and low leverage.
  • The company's profitability is robust, with a return on equity of 16.82% and a return on assets of 12.99%.
  • The stock is moderately valued, with a price-to-earnings ratio of 19.36 and a price-to-book ratio of 3.26.
  • Analysts have a positive outlook, with a mean price target of 74.69 CNY and a median of 75.00 CNY.
  • The company is heavily concentrated in the Chinese market, which may pose regulatory and economic risks.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$6.70B
Gross profit$4.92B
Operating income$2.07B
Net income$1.74B
R&D
SG&A
D&A
SBC
Operating cash flow$2.29B
CapEx-$82.7M
Free cash flow$163.1M
Total assets$13.38B
Total liabilities$3.04B
Total equity$10.34B
Cash & equivalents
Long-term debt$62.3M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$6.70B$2.07B$1.74B$163.1M
FY-1$6.16B$1.85B$1.56B-$321.6M
FY-2$4.72B$1.36B$1.15B$497.4M
FY-3$4.04B$913.8M$780.0M$476.9M
FY-4$3.85B$565.1M$440.4M$374.1M
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$13.38B$10.34B
FY-1$13.09B$10.31B
FY-2$13.31B$10.72B
FY-3$12.63B$10.33B
FY-4$11.63B$9.97B
PeriodOCFCapExFCFSBC
FY0$2.29B-$82.7M$163.1M
FY-1$2.85B-$97.4M-$321.6M
FY-2$1.95B-$54.5M$497.4M
FY-3$2.14B-$45.6M$476.9M
FY-4$2.80B-$24.7M$374.1M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$1.81B$544.4M$454.8M
FQ-1$1.93B$565.5M$464.9M
FQ-2$1.72B$526.9M$456.1M
FQ-3$1.33B$470.7M$392.7M
FQ-4$1.72B$507.7M$424.5M
FQ-5$1.83B$506.3M$405.1M
FQ-6$1.58B$463.9M$413.6M
FQ-7$1.29B$468.8M$385.0M
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$13.55B$10.79B$6.15B
FQ-1$13.38B$10.34B
FQ-2$12.75B$9.95B$5.56B
FQ-3$12.78B$10.31B
FQ-4$13.31B$10.74B$5.43B
FQ-5$13.09B$10.31B
FQ-6$12.72B$9.91B$4.30B
FQ-7$12.50B$10.24B
PeriodOCFCapExFCFSBC
FQ0$28.9M-$44.3M
FQ-1$2.29B-$82.7M
FQ-2$1.31B-$44.0M
FQ-3$965.4M-$22.1M
FQ-4-$304.1M-$11.7M
FQ-5$2.85B-$97.4M
FQ-6$1.44B-$63.1M
FQ-7$922.1M-$42.3M
Valuation
Market price$52.26
Market cap$33.65B
Enterprise value$33.72B
P/E19.4
Reported non-GAAP P/E
EV/Revenue5.0
EV/Op income16.3
EV/OCF14.7
P/B3.3
P/Tangible book3.3
Tangible book$10.34B
Net cash-$62.3M
Current ratio3.7
Debt/Equity0.0
ROA13.0%
ROE16.8%
Cash conversion1.3%
CapEx/Revenue-1.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 1 companies
Metric000423Activity
Op margin30.9%-2.9% medp25 -218.9% · p75 9.6%top quartile
Net margin25.9%28.2% medp25 28.2% · p75 28.2%bottom quartile
Gross margin73.4%47.8% medp25 27.6% · p75 68.9%top quartile
CapEx / revenue-1.2%6.6% medp25 6.6% · p75 6.6%bottom quartile
Debt / equity1.0%271.5% medp25 271.5% · p75 271.5%bottom quartile
Observations
IR observations
Mean price target74.69 CNY
Median price target75.00 CNY
High price target82.96 CNY
Low price target64.00 CNY
Mean recommendation1.78 (1=strong buy, 5=strong sell)
Strong-buy count2.00
Buy count7.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate3.11 CNY
Last actual EPS2.70 CNY
Source: analysis-pipeline (hybrid)Generated: 2026-05-17 02:36 UTCJob: 2b411c8f